| Year |
Citation |
Score |
| 2011 |
Eijsbouts AM, Kempers MJ, van den Hoogen FH, Laan RF, Hermus AR, Ross HA, Sweep FC, van de Putte LB. Effects of naproxen and sulphasalazine or methotrexate on hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology. 29: 35-42. PMID 21345290 |
0.313 |
|
| 2011 |
Dawidowicz K, Allanore Y, Guedj M, Pierlot C, Bombardieri S, Balsa A, Westhovens R, Barrera P, Alves H, Teixeira VH, Petit-Teixeira E, van de Putte L, van Riel P, Prum B, Bardin T, et al. The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotype. Annals of the Rheumatic Diseases. 70: 117-21. PMID 20980283 DOI: 10.1136/ard.2010.129171 |
0.511 |
|
| 2010 |
Landewé RB, Houbiers JG, Van den Bosch F, in't Hout J, Verschueren PC, Meijerink JH, van den Hoogen FH, Masek BA, Bruyn GA, Wouters JM, Voskuyl AE, van Laar JM, Bijlsma JJ, van der Heijde DM, Breedveld FC, ... van de Putte LB, et al. Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. Annals of the Rheumatic Diseases. 69: 1655-9. PMID 19778914 DOI: 10.1136/ard.2009.117234 |
0.391 |
|
| 2009 |
Burkhardt J, Petit-Teixeira E, Teixeira VH, Kirsten H, Garnier S, Ruehle S, Oeser C, Wolfram G, Scholz M, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Pascual-Salcedo D, ... ... van de Putte L, et al. Association of the X-chromosomal genes TIMP1 and IL9R with rheumatoid arthritis. The Journal of Rheumatology. 36: 2149-57. PMID 19723899 DOI: 10.3899/Jrheum.090059 |
0.51 |
|
| 2009 |
Teixeira VH, Pierlot C, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Vaz C, Fernandes M, Pascual-Salcedo D, Bombardieri S, Dequeker J, Radstake TR, Van Riel P, van de Putte L, et al. Testing for the association of the KIAA1109/Tenr/IL2/IL21 gene region with rheumatoid arthritis in a European family-based study. Arthritis Research & Therapy. 11: R45. PMID 19302705 DOI: 10.1186/ar2654 |
0.436 |
|
| 2007 |
Jacq L, Garnier S, Dieudé P, Michou L, Pierlot C, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Vaz C, Fernandes M, Pascual-Salcedo D, Bombardieri S, Dequeker J, ... ... van de Putte L, et al. The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: a family-based study. Arthritis Research & Therapy. 9: R63. PMID 17615072 DOI: 10.1186/ar2221 |
0.512 |
|
| 2007 |
Michou L, Lasbleiz S, Rat AC, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Pierlot C, Glikmans E, Garnier S, Dausset J, Vaz C, Fernandes M, Petit-Teixeira E, ... ... van de Putte L, et al. Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proceedings of the National Academy of Sciences of the United States of America. 104: 1649-54. PMID 17237219 DOI: 10.1073/Pnas.0610250104 |
0.519 |
|
| 2006 |
Zandbelt MM, Houbiers JG, van den Hoogen FH, Meijerink J, van Riel PL, in't Hout J, van de Putte LB. Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis. The Journal of Rheumatology. 33: 1726-33. PMID 16960935 |
0.593 |
|
| 2005 |
Eijsbouts AM, van den Hoogen FH, Laan RF, Hermus AR, Sweep CG, van de Putte LB. Hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology. 23: 658-64. PMID 16173242 |
0.33 |
|
| 2005 |
Eijsbouts AM, van den Hoogen FH, Laan RF, Sweep CG, Hermus AR, van de Putte LB. Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity. Annals of the Rheumatic Diseases. 64: 433-7. PMID 15319231 DOI: 10.1136/ard.2002.001347 |
0.379 |
|
| 2005 |
Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Annals of the Rheumatic Diseases. 64: 127-9. PMID 15051621 DOI: 10.1136/Ard.2004.020503 |
0.632 |
|
| 2004 |
Rau R, Simianer S, van Riel PL, van de Putte LB, Krüger K, Schattenkirchner M, Allaart CF, Breedveld FC, Kempeni J, Beck K, Kupper H. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scandinavian Journal of Rheumatology. 33: 145-53. PMID 15228184 |
0.501 |
|
| 2004 |
Hartman M, van Ede A, Severens JL, Laan RF, van de Putte L, van der Wilt GJ. Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis. The Journal of Rheumatology. 31: 902-8. PMID 15124248 |
0.353 |
|
| 2004 |
van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Annals of the Rheumatic Diseases. 63: 508-16. PMID 15082480 DOI: 10.1136/ard.2003.013052 |
0.545 |
|
| 2004 |
Van De Putte L, Nichol MB. Adalimumab for Rheumatoid Arthritis: Considerations for Reimbursement by Third-Party Payors Disease Management and Health Outcomes. 12: 1-8. DOI: 10.2165/00115677-200412010-00001 |
0.33 |
|
| 2003 |
van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Moutsopoulos HM, Beck K, Kupper H. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Annals of the Rheumatic Diseases. 62: 1168-77. PMID 14644854 |
0.537 |
|
| 2003 |
de Vries N, Tak PP, Tijssen H, van Riel PL, van de Putte LB. Female sex increases risk for rheumatoid arthritis only in individuals encoding low-risk HLA-DRB1 alleles. Arthritis and Rheumatism. 48: 1762-3. PMID 12794845 DOI: 10.1002/art.11022 |
0.433 |
|
| 2003 |
Rau R, Sander O, Van Riel P, Van de Putte L, Hasler F, Zaug M, Kneer J, Van der Auwera P, Stevens RM, Baudin M, Dickson S, Herbold D, Kaehny MR, Luedin E, McAuliffe T. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): A double blind, placebo controlled dose-finding study in rheumatoid arthritis Journal of Rheumatology. 30: 680-690. PMID 12672184 |
0.536 |
|
| 2003 |
den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, Kempeni J, Kupper H. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. The Journal of Rheumatology. 29: 2288-98. PMID 12415583 |
0.501 |
|
| 2002 |
van Ede AE, Laan RF, De Abreu RA, Stegeman AB, van de Putte LB. Purine enzymes in patients with rheumatoid arthritis treated with methotrexate. Annals of the Rheumatic Diseases. 61: 1060-4. PMID 12429535 |
0.311 |
|
| 2002 |
Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford, England). 41: 430-9. PMID 11961174 |
0.517 |
|
| 2002 |
de Vries N, van Riel PL, van de Putte LB. Research in complex diseases. Lancet. 359: 1243-5. PMID 11955559 DOI: 10.1016/S0140-6736(02)08223-5 |
0.428 |
|
| 2002 |
de Vries N, Tijssen H, van Riel PL, van de Putte LB. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67-74 of the HLA-DRB1 molecule. Arthritis and Rheumatism. 46: 921-8. PMID 11953968 DOI: 10.1002/art.10210 |
0.496 |
|
| 2002 |
den Broeder AA, Joosten LA, Saxne T, Heinegård D, Fenner H, Miltenburg AM, Frasa WL, van Tits LJ, Buurman WA, van Riel PL, van de Putte LB, Barrera P. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Annals of the Rheumatic Diseases. 61: 311-8. PMID 11874832 |
0.535 |
|
| 2001 |
Tijhuis GJ, van de Putte LB, Breedveld FC. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept]. Nederlands Tijdschrift Voor Geneeskunde. 145: 1880-5. PMID 11605312 |
0.397 |
|
| 2001 |
van Heereveld HA, Laan RF, van den Hoogen FH, Malefijt MC, Novakova IR, van de Putte LB. Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement. Annals of the Rheumatic Diseases. 60: 974-6. PMID 11557656 |
0.301 |
|
| 2001 |
Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, Schattenkirchner M, Nash P, Oed C, Loew-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Annals of the Rheumatic Diseases. 60: 913-23. PMID 11557646 |
0.317 |
|
| 2001 |
Kroot EJ, van Gestel AM, Swinkels HL, Albers MM, van de Putte LB, van Riel PL. Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. The Journal of Rheumatology. 28: 1511-7. PMID 11469455 |
0.546 |
|
| 2001 |
Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 60: 660-9. PMID 11406520 |
0.523 |
|
| 2001 |
Barrera P, Balsa A, Alves H, Westhovens R, Maenaut K, Cornélis F, Fritz P, Bardin T, Ceu Maia M, Lopes-Vaz A, Pascual Salcedo D, de la Concha E, Radstake T, van de Putte LB, Migliorini P, et al. Noninherited maternal antigens do not increase the susceptibility for familial rheumatoid arthritis. European Consortium on Rheumatoid Arthritis Families (ECRAF). The Journal of Rheumatology. 28: 968-74. PMID 11361224 |
0.313 |
|
| 2001 |
Radstake TR, Barrera P, Albers MJ, Swinkels HL, van de Putte LB, van Riel PL. Genetic anticipation in rheumatoid arthritis in Europe. European Consortium on Rheumatoid Arthritis Families. The Journal of Rheumatology. 28: 962-7. PMID 11361223 |
0.535 |
|
| 2001 |
Laan RF, van Riel PL, van de Putte LB. Leflunomide and methotrexate. Current Opinion in Rheumatology. 13: 159-63. PMID 11333342 |
0.499 |
|
| 2001 |
Verburg RJ, Kruize AA, van den Hoogen FH, Fibbe WE, Petersen EJ, Preijers F, Sont JK, Barge RM, Bijlsma JW, van de Putte LB, Breedveld FC, van Laar JM. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis and Rheumatism. 44: 754-60. PMID 11315914 DOI: 10.1002/1529-0131(200104)44:4<754::AID-ANR131>3.0.CO;2-N |
0.329 |
|
| 2001 |
den Broeder AA, van den Hoogen FH, van de Putte LB. Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment. Annals of the Rheumatic Diseases. 60: 538-9. PMID 11302883 |
0.347 |
|
| 2000 |
Kroot EJ, van Leeuwen MA, van Rijswijk MH, Prevoo ML, Van 't Hof MA, van De Putte LB, van Riel PL. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Annals of the Rheumatic Diseases. 59: 954-8. PMID 11087698 |
0.48 |
|
| 2000 |
Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism. 43: 1831-5. PMID 10943873 DOI: 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6 |
0.541 |
|
| 2000 |
Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR, Klareskog L, Maini RN, Numo R, van De Putte LB, van Riel PL, Rodriguez-Valverde V. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Annals of the Rheumatic Diseases. 59: 504-5. PMID 10873957 DOI: 10.1136/ard.59.7.504 |
0.483 |
|
| 2000 |
Radstake TR, Barrera P, Albers JM, Swinkels HL, van de Putte LB, van Riel PL. Familial vs sporadic rheumatoid arthritis (RA). A prospective study in an early RA inception cohort. Rheumatology (Oxford, England). 39: 267-73. PMID 10788534 |
0.537 |
|
| 2000 |
van der Heijde DM, van Riel PL, Nuver-Zwart IH, van de Putte LB. Alternative methods for analysis of radiographic damage in a randomized, double blind, parallel group clinical trial comparing hydroxychloroquine and sulfasalazine. The Journal of Rheumatology. 27: 535-8; discussion 53. PMID 10685829 |
0.426 |
|
| 1999 |
Kroot EJ, van de Putte LB, van Riel PL. Management of therapy-resistant rheumatoid arthritis. Bailliã¨Re's Best Practice & Research. Clinical Rheumatology. 13: 737-52. PMID 10652651 DOI: 10.1053/berh.1999.0057 |
0.552 |
|
| 1999 |
van de Putte LB, Kroot EJ, van Riel PL. Management of refractory rheumatoid arthritis. Rheumatology (Oxford, England). 38: 32-4. PMID 10646488 |
0.556 |
|
| 1999 |
Furst DE, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, Kalden JR, Kavanaugh A, Keystone E, Lipsky PE, Maini RN, Moreland L, Smolen JS, Van De Putte L, Vischer T, et al. Access to disease modifying treatments for rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 58: I129-30. PMID 10577989 DOI: 10.1136/ARD.58.2008.I129 |
0.38 |
|
| 1999 |
de Vries N, van Elderen C, Tijssen H, van Riel PL, van de Putte LB. No support for HLA-DQ encoded susceptibility in rheumatoid arthritis. Arthritis and Rheumatism. 42: 1621-7. PMID 10446860 DOI: 10.1002/1529-0131(199908)42:8<1621::AID-ANR9>3.0.CO;2-0 |
0.477 |
|
| 1999 |
Barrera P, Radstake TR, Albers JM, van Riel PL, van de Putte LB. Familial aggregation of rheumatoid arthritis in The Netherlands: a cross-sectional hospital-based survey. European Consortium on Rheumatoid Arthritis families (ECRAF). Rheumatology (Oxford, England). 38: 415-22. PMID 10371279 |
0.518 |
|
| 1999 |
Haagsma CJ, Blom HJ, van Riel PL, van't Hof MA, Giesendorf BA, van Oppenraaij-Emmerzaal D, van de Putte LB. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 58: 79-84. PMID 10343521 |
0.482 |
|
| 1998 |
van de Putte LB, van Gestel AM, van Riel PL. Early treatment of rheumatoid arthritis: rationale, evidence, and implications. Annals of the Rheumatic Diseases. 57: 511-2. PMID 9849307 |
0.534 |
|
| 1998 |
Stolk JN, Boerbooms AM, de Abreu RA, de Koning DG, van Beusekom HJ, Muller WH, van de Putte LB. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis and Rheumatism. 41: 1858-66. PMID 9778228 DOI: 10.1002/1529-0131(199810)41:10<1858::AID-ART19>3.0.CO;2-8 |
0.384 |
|
| 1998 |
Jansen TL, van Heereveld HA, Laan RF, Barrera P, van de Putte LB. Septic arthritis with Listeria monocytogenes during low-dose methotrexate. Journal of Internal Medicine. 244: 87-90. PMID 9698030 |
0.334 |
|
| 1998 |
van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Seminars in Arthritis and Rheumatism. 27: 277-92. PMID 9572710 |
0.316 |
|
| 1997 |
Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 36: 1082-8. PMID 9374925 |
0.59 |
|
| 1997 |
van de Putte LB, van Riel PL. Currently used second-line agents: do they control the disease course? Clinical and Experimental Rheumatology. 15: S71-4. PMID 9266136 |
0.527 |
|
| 1997 |
de Vries N, Tijssen H, Jarvinen P, Aho K, van de Putte LB. HLA-DRB1 in eight Finnish monozygotic twin pairs concordant for rheumatoid arthritis. Tissue Antigens. 49: 277-9. PMID 9098938 |
0.326 |
|
| 1997 |
van Leeuwen MA, van Rijswijk MH, Sluiter WJ, van Riel PL, Kuper IH, van de Putte LB, Pepys MB, Limburg PC. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. The Journal of Rheumatology. 24: 20-7. PMID 9002006 |
0.494 |
|
| 1996 |
Stolk JN, Boerbooms AM, De Abreu RA, Kerstens PJ, de Koning DG, de Graaf R, Mulder J, van de Putte LB. Purine enzyme activities in recent onset rheumatoid arthritis: are there differences between patients and healthy controls? Annals of the Rheumatic Diseases. 55: 733-8. PMID 8984938 |
0.331 |
|
| 1996 |
Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology. 35: 1101-5. PMID 8948296 |
0.535 |
|
| 1996 |
van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. British Journal of Rheumatology. 35: 4-7. PMID 8810683 |
0.538 |
|
| 1996 |
Creemers MC, van 't Hof MA, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL. Disease activity in ankylosing spondylitis: selection of a core set of variables and a first set in the development of a disease activity score. British Journal of Rheumatology. 35: 867-73. PMID 8810670 DOI: 10.1093/Rheumatology/35.9.867 |
0.653 |
|
| 1995 |
van de Putte LB, van Riel PL. Rheumatoid arthritis: new trends in therapy. Clinical and Experimental Rheumatology. 13: S27-30. PMID 8846541 |
0.353 |
|
| 1995 |
van Riel PL, van der Heijde DM, Nuver-Zwart IH, van de Putte LB. Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. The Journal of Rheumatology. 22: 1797-9. PMID 8523366 |
0.304 |
|
| 1995 |
van Gestel AM, Laan RF, Haagsma CJ, van de Putte LB, van Riel PL. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. British Journal of Rheumatology. 34: 347-51. PMID 7788149 |
0.31 |
|
| 1995 |
Kerstens PJ, Stolk JN, Boerbooms AM, De Abreu RA, Van de Putte LB. Purine enzymes in rheumatoid arthritis. A clue to the prediction of the response to azathioprine? Review and hypothesis. Clinical and Experimental Rheumatology. 13: 107-11. PMID 7774088 |
0.315 |
|
| 1995 |
Creemers MC, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL. Methotrexate in severe ankylosing spondylitis: an open study. The Journal of Rheumatology. 22: 1104-7. PMID 7674237 |
0.703 |
|
| 1995 |
Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 24: 411-21. PMID 7667645 |
0.307 |
|
| 1994 |
Creemers MC, Van 't Hof MA, Franssen MJ, Van de Putte LB, Gribnau FW, Van Riel PL. A Dutch version of the functional index for ankylosing spondylitis: development and validation in a long-term study. British Journal of Rheumatology. 33: 842-6. PMID 8081670 DOI: 10.1093/Rheumatology/33.9.842 |
0.671 |
|
| 1994 |
van den Hoogen FH, Spronk PE, Boerbooms AM, Bootsma H, de Rooij DJ, Kallenberg CG, van de Putte LB. Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies. British Journal of Rheumatology. 33: 1117-20. PMID 8000737 |
0.302 |
|
| 1994 |
Haagsma CJ, van Riel PL, de Rooij DJ, Vree TB, Russel FJ, van't Hof MA, van de Putte LB. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. British Journal of Rheumatology. 33: 1049-55. PMID 7981992 |
0.385 |
|
| 1994 |
Kerstens PJ, Stolk JN, Boerbooms AM, Lambooy LH, de Graaf R, De Abreu RA, van de Putte LB. Purine enzymes in rheumatoid arthritis: possible association with response to azathioprine. A pilot study. Annals of the Rheumatic Diseases. 53: 608-11. PMID 7979599 |
0.347 |
|
| 1994 |
Barrera P, Van Ede A, Laan RF, Van Riel PL, Boerbooms AM, Van De Putte LB. Methotrexate-related pulmonary complications in patients with rheumatoid arthritis: cluster of five cases in a period of three months. Annals of the Rheumatic Diseases. 53: 479-80. PMID 7944625 |
0.472 |
|
| 1994 |
Creemers MC, van Riel PL, Franssen MJ, van de Putte LB, Gribnau FW. Second-line treatment in seronegative spondylarthropathies. Seminars in Arthritis and Rheumatism. 24: 71-81. PMID 7839156 DOI: 10.1016/S0049-0172(05)80001-0 |
0.658 |
|
| 1994 |
Kerstens PJ, Boerbooms AM, Jeurissen ME, Westgeest TA, Van Erp A, Mulder J, van de Putte LB. Antiperinuclear factor and disease activity in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. The Journal of Rheumatology. 21: 2190-4. PMID 7699617 |
0.34 |
|
| 1993 |
Laan RF, Buijs WC, Verbeek AL, Draad MP, Corstens FH, van de Putte LB, van Riel PL. Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Annals of the Rheumatic Diseases. 52: 21-6. PMID 8427509 |
0.315 |
|
| 1993 |
Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Annals of Internal Medicine. 119: 963-8. PMID 8105737 DOI: 10.7326/0003-4819-119-10-199311150-00001 |
0.471 |
|
| 1993 |
Wijnands MJ, Van 'T Hof MA, Van De Putte LB, Van Riel PL. Rheumatoid arthritis: a risk factor for sulphasalazine toxicity? A meta-analysis. British Journal of Rheumatology. 32: 313-8. PMID 8096419 |
0.404 |
|
| 1992 |
Laan RF, van Riel PL, van Erning LJ, Lemmens JA, Ruijs SH, van de Putte LB. Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. British Journal of Rheumatology. 31: 91-6. PMID 1737238 DOI: 10.1093/Rheumatology/31.2.91 |
0.303 |
|
| 1992 |
van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Annals of the Rheumatic Diseases. 51: 177-81. PMID 1550400 |
0.3 |
|
| 1992 |
Scott DL, Panayi GS, van Riel PL, Smolen J, van de Putte LB. Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clinical and Experimental Rheumatology. 10: 521-5. PMID 1458708 |
0.374 |
|
| 1992 |
Kerstens PJ, Boerbooms AM, Jeurissen ME, Fast JH, Assmann KJ, van de Putte LB. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases. The Journal of Rheumatology. 19: 867-71. PMID 1404122 |
0.357 |
|
| 1991 |
Jeurissen ME, Boerbooms AM, van de Putte LB, Doesburg WH, Lemmens AM. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Annals of Internal Medicine. 114: 999-1004. PMID 2029111 |
0.349 |
|
| 1991 |
Jacobs JW, Rasker JJ, Van Riel PL, Gribnau FW, van de Putte LB. [Alternative treatment methods in rheumatic diseases; a literature review]. Nederlands Tijdschrift Voor Geneeskunde. 135: 317-22. PMID 2008219 |
0.683 |
|
| 1991 |
Jeurissen ME, Boerbooms AM, van de Putte LB, Doesburg WH, Mulder J, Rasker JJ, Kruijsen MW, Haverman JF, van Beusekom HJ, Muller WH. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis and Rheumatism. 34: 961-72. PMID 1859490 |
0.374 |
|
| 1991 |
Jacobs JW, Rasker JJ, van Riel PL, Gribnau FW, van de Putte LB. Rheumajecta and vasolastine in the treatment of rheumatoid arthritis--the results of a placebo-controlled, double-blind trial of a complementary treatment. Scandinavian Journal of Rheumatology. 20: 434-40. PMID 1771401 DOI: 10.3109/03009749109096823 |
0.716 |
|
| 1991 |
van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LB. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. The Journal of Rheumatology. 18: 1285-9. PMID 1757926 |
0.301 |
|
| 1991 |
Wijnands MJ, Nuver-Zwart IH, van Riel PL, van 't Hof MA, Gribnau FW, van De Putte LB. Hemolysis during low-dose sulfasalazine treatment in rheumatoid arthritis patients. Scandinavian Journal of Rheumatology. 20: 52-7. PMID 1672775 DOI: 10.3109/03009749109165922 |
0.71 |
|
| 1990 |
Wijnands MJ, van Riel PL, Gribnau FW, van de Putte LB. [Risk factors for the development of side effects during treatment of rheumatoid arthritis with second-line antirheumatic agents; a review of the literature]. Nederlands Tijdschrift Voor Geneeskunde. 134: 1387-91. PMID 2197565 |
0.678 |
|
| 1990 |
Wijnands MJ, van Riel PL, Gribnau FW, van de Putte LB. Risk factors of second-line antirheumatic drugs in rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 19: 337-52. PMID 2196675 DOI: 10.1016/0049-0172(90)90071-M |
0.668 |
|
| 1990 |
Jacobs JW, Rasker JJ, van Riel PL, Gribnau FW, van de Putte LB. [Rheumajecta and Vasolastine treatment of primary fibromyalgia; results of a randomized placebo-controlled double-blind study]. Nederlands Tijdschrift Voor Geneeskunde. 134: 693-7. PMID 2157988 |
0.631 |
|
| 1990 |
Wijnands MJ, Allebes WA, Boerbooms AM, van de Putte LB, van Riel PL. Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine. Annals of the Rheumatic Diseases. 49: 798-800. PMID 1978639 |
0.474 |
|
| 1990 |
van Riel PL, van de Putte LB. Sulphasalazine in the treatment of rheumatoid arthritis: a renewed challenge. The Netherlands Journal of Medicine. 36: 221-2. PMID 1975649 |
0.33 |
|
| 1990 |
van der Heijde DM, van Riel PL, Nuver-Zwart IH, van de Putte LB. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet. 335: 539. PMID 1968547 |
0.303 |
|
| 1989 |
Faaber P, van den Bersselaar LA, van de Putte LB, van den Berg WB. Immune complex formation between IgM rheumatoid factor and IgG generated by hyaluronic acid. Arthritis and Rheumatism. 32: 1521-7. PMID 2688658 |
0.301 |
|
| 1989 |
Van Riel PL, Van der Heijde DM, Van de Putte LB. Disease assessment in rheumatoid arthritis. Annals of the Rheumatic Diseases. 48: 962. PMID 2596886 |
0.303 |
|
| 1989 |
Nuver-Zwart IH, van Riel PL, van de Putte LB, Gribnau FW. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Annals of the Rheumatic Diseases. 48: 389-95. PMID 2567150 DOI: 10.1136/Ard.48.5.389 |
0.709 |
|
| 1989 |
Westgeest AA, van Loon AM, van der Logt JT, van de Putte LB, Boerbooms AM. Antiperinuclear factor, a rheumatoid arthritis specific autoantibody: its relation to Epstein-Barr virus. The Journal of Rheumatology. 16: 626-30. PMID 2547060 |
0.327 |
|
| 1988 |
Boerbooms AM, Jeurissen ME, Westgeest AA, Theunisse H, Van de Putte LB. Methotrexate in refractory rheumatoid arthritis. Clinical Rheumatology. 7: 249-56. PMID 3416568 |
0.319 |
|
| 1988 |
Van den Ouweland FA, Jansen PA, Tan Y, Van de Putte LB, Van Ginneken CA, Gribnau FW. Pharmacokinetics of high-dosage naproxen in elderly patients. International Journal of Clinical Pharmacology, Therapy, and Toxicology. 26: 143-7. PMID 3410597 |
0.574 |
|
| 1988 |
Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia related to azathioprine in rheumatoid arthritis. Annals of the Rheumatic Diseases. 47: 503-5. PMID 3382271 |
0.345 |
|
| 1988 |
Nuver-Zwart I, Schalkwijk J, Joosten LA, van den Berg WB, van de Putte LB. Effects of synovial fluid and synovial fluid cells on chondrocyte metabolism in short term tissue culture. The Journal of Rheumatology. 15: 210-6. PMID 3361531 |
0.314 |
|
| 1988 |
Van den Ouweland FA, Gribnau FW, Van Ginneken CA, Tan Y, Van de Putte LB. Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. Clinical Pharmacology and Therapeutics. 43: 79-85. PMID 3335121 DOI: 10.1038/Clpt.1988.14 |
0.613 |
|
| 1988 |
Wijnands MJ, Corstens FH, van der Heijde DM, van de Putte LB, Lenders JW. Lymphatic obstruction as a cause of oedema in rheumatoid arthritis. The Netherlands Journal of Medicine. 33: 140-3. PMID 3226447 |
0.31 |
|
| 1988 |
van Riel PL, Nuver-Zwart HH, van de Putte LB, Gribnau FW. [Sulfasalazine as an antirheumatism agent; a review of the literature]. Nederlands Tijdschrift Voor Geneeskunde. 132: 594-5. PMID 2896302 |
0.601 |
|
| 1987 |
van den Ouweland FA, Franssen MJ, van de Putte LB, Tan Y, van Ginneken CA, Gribnau FW. Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation. British Journal of Clinical Pharmacology. 23: 189-93. PMID 3828195 |
0.62 |
|
| 1987 |
Van Riel PL, Gribnau FW, Van de Putte LB, Arts CW, Van Aernsbergen A. Serum gold concentrations during treatment with auranofin. Clinical Rheumatology. 6: 50-4. PMID 3581698 DOI: 10.1007/Bf02201000 |
0.66 |
|
| 1987 |
Westgeest AA, Boerbooms AM, Jongmans M, Vandenbroucke JP, Vierwinden G, van de Putte LB. Antiperinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis. The Journal of Rheumatology. 14: 893-7. PMID 3501470 |
0.366 |
|
| 1987 |
van den Ouweland FA, Corstens FH, van de Putte LB, Gribnau FW. Gastrointestinal blood loss during treatment with naproxen for rheumatoid arthritis. Scandinavian Journal of Rheumatology. 16: 365-70. PMID 3500510 DOI: 10.3109/03009748709102509 |
0.625 |
|
| 1987 |
Franssen MJ, Boerbooms AM, Van de Putte LB. Polychondritis and rheumatoid arthritis. Case report and review of the literature. Clinical Rheumatology. 6: 453-7. PMID 3327645 |
0.318 |
|
| 1986 |
Van den Ouweland FA, Gribnau FW, Tan Y, Van Ginneken CA, Van de Putte LB. Hypoalbuminaemia and naproxen pharmacokinetics in a patient with rheumatoid arthritis. Clinical Pharmacokinetics. 11: 511-5. PMID 3802691 DOI: 10.2165/00003088-198611060-00007 |
0.67 |
|
| 1985 |
Franssen MJ, van de Putte LB, Gribnau FW. IgA serum levels and disease activity in ankylosing spondylitis: a prospective study. Annals of the Rheumatic Diseases. 44: 766-71. PMID 4062389 DOI: 10.1136/ard.44.11.766 |
0.603 |
|
| 1985 |
Speerstra F, Reekers P, van de Putte LB, Vandenbroucke JP. HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. Tissue Antigens. 26: 35-40. PMID 3929421 DOI: 10.1111/J.1399-0039.1985.TB00932.X |
0.335 |
|
| 1985 |
Friesen WT, Hekster YA, van de Putte LB, Gribnau FW. Cross-sectional study of rheumatoid arthritis treatment in a university hospital. Annals of the Rheumatic Diseases. 44: 372-8. PMID 3874606 DOI: 10.1136/Ard.44.6.372 |
0.67 |
|
| 1984 |
van Riel PL, van de Putte LB, Gribnau FW, de Waal RM. IgA deficiency during aurothioglucose treatment. A case report. Scandinavian Journal of Rheumatology. 13: 334-6. PMID 6441247 DOI: 10.3109/03009748409111305 |
0.652 |
|
| 1983 |
van Riel PL, Reekers P, van de Putte LB, Gribnau FW. Association of HLA antigens, toxic reactions and therapeutic response to auranofin and aurothioglucose in patients with rheumatoid arthritis. Tissue Antigens. 22: 194-9. PMID 6415865 DOI: 10.1111/J.1399-0039.1983.Tb01191.X |
0.679 |
|
| 1973 |
van de Putte LB, Brutel de la Rivière G, van Breda Vriesman PJ, de Graeff J. Haematuria of renal parenchymal origin in adults with normal renal function. Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association. 10: 391-8. PMID 4278118 |
0.526 |
|
| Show low-probability matches. |
